Vertigo/Vestibular Disorders and Cognitive Impairment in the Elderly

38.1K
views
78
authors
13
articles
Cover image for research topic "Vertigo/Vestibular Disorders and Cognitive Impairment in the Elderly"
Editors
5
Impact
Loading...
5,494 views
11 citations

Background and purpose: The prevalence of cerebral small vessel disease (CSVD) is increasing due to the accelerating global aging process, resulting in a substantial burden on all countries, as cognitive dysfunction associated with CSVD is also on the rise. Clock genes have a significant impact on cognitive decline and dementia. Furthermore, the pattern of DNA methylation in clock genes is strongly associated with cognitive impairment. Thus, the aim of this study was to explore the connection between DNA promoter methylation of PER1 and CRY1 and cognitive dysfunction in patients with CSVD.

Methods: We recruited patients with CSVD admitted to the Geriatrics Department of the Lianyungang Second People’s Hospital between March 2021 and June 2022. Based on their Mini-Mental State Examination score, patients were categorized into two groups: 65 cases with cognitive dysfunction and 36 cases with normal cognitive function. Clinical data, 24-h ambulatory blood pressure monitoring parameters, and CSVD total load scores were collected. Moreover, we employed methylation-specific PCR to analyze the peripheral blood promoter methylation levels of clock genes PER1 and CRY1 in all CSVD patients who were enrolled. Finally, we used binary logistic regression models to assess the association between the promoter methylation of clock genes (PER1 and CRY1) and cognitive dysfunction in patients with CSVD.

Results: (1) A total of 101 individuals with CSVD were included in this study. There were no statistical differences between the two groups in baseline clinical data except MMSE and AD8 scores. (2) After B/H correction, the promoter methylation rate of PER1 was higher in the cognitive dysfunction group than that in the normal group, and the difference was statistically significant (adjusted p < 0.001). (3) There was no significant correlation between the promoter methylation rates of PER1 and CRY1 in peripheral blood and circadian rhythm of blood pressure (p > 0.05). (4) Binary logistic regression models showed that the influence of promoter methylation of PER1 and CRY1 on cognitive dysfunction were statistically significant in Model 1 (p < 0.001; p = 0.025), and it still existed after adjusting for confounding factors in Model 2. Patients with the promoter methylation of PER1 gene (OR = 16.565, 95%CI, 4.057–67.628; p < 0.001) and the promoter methylation of CRY1 gene (OR = 6.017, 95%CI, 1.290–28.069; p = 0.022) were at greater risk of cognitive dysfunction compared with those with unmethylated promoters of corresponding genes in Model 2.

Conclusion: The promoter methylation rate of PER1 gene was higher in the cognitive dysfunction group among CSVD patients. And the hypermethylation of the promoters of clock genes PER1 and CRY1 may be involved in affecting cognitive dysfunction in patients with CSVD.

2,587 views
7 citations
Review
20 April 2023

Alzheimer’s disease (AD) or vestibular dysfunction may impair visual–spatial cognitive function. Recent studies have shown that vestibular dysfunction is increasingly common in patients with AD, and patients with AD with vestibular impairment show more visual–spatial cognitive impairment. By exploring the relationship and interaction mechanism among the vestibular system, visual–spatial cognitive ability, and AD, this study aims to provide new insights for the screening, diagnosis, and rehabilitation intervention of patients with AD. In contrast, routine vestibular function tests are particularly important for understanding the vestibular function of patients with AD. The efficacy of vestibular function test as a tool for the early screening of patients with AD must also be further studied. Through the visual–spatial cognitive ability test, the “spatial impairment” subtype of patients with AD, which may be significant in caring for patients with AD to prevent loss and falls, can also be determined. Additionally, the visual–spatial cognitive ability test has great benefits in preventing and alleviating cognitive decline of patients with AD.

4,994 views
18 citations
4,069 views
5 citations
Open for submission
Frontiers Logo

Frontiers in Endocrinology

Insights in Diabetes: Molecular Mechanisms 2021
Edited by Undurti Narasimha Das, Gundu H. R. Rao, Denis Baranenko
49.8K
views
66
authors
10
articles
Recommended Research Topics
Frontiers Logo

Frontiers in Endocrinology

Insights in Diabetes: Molecular Mechanisms 2021
Edited by Undurti Narasimha Das, Gundu H. R. Rao, Denis Baranenko
49.8K
views
66
authors
10
articles
Frontiers Logo

Frontiers in Endocrinology

Molecular Mechanisms and Genetics of Heart Failure Caused by Diabetes
Edited by Qiulun Lu, YE DING, Changhan Ouyang
14.6K
views
30
authors
5
articles
Frontiers Logo

Frontiers in Endocrinology

Progression to Diabetes: Molecular and Cellular Mechanisms
Edited by Carlos Guillén, Adolfo Garcia-Ocana
39K
views
62
authors
10
articles
Frontiers Logo

Frontiers in Endocrinology

Insights in Diabetes: Molecular Mechanisms 2022
Edited by Undurti Narasimha Das, Gundu H. R. Rao, Denis Baranenko
21.3K
views
29
authors
6
articles
Frontiers Logo

Frontiers in Endocrinology

A Year in Review: Discussions in Diabetes: Molecular Mechanisms
Edited by Marcia Hiriart, Inês Cebola
106.6K
views
48
authors
8
articles